The proteolytic activation of highly purified, heterodimeric porcine factor VIII and factor VIII-von Willebrand factor complex by thrombin was compared at I 0.17, pH 7.0, 22 degrees C. During the activation of factor VIII, heavy-chain cleavage is necessary to activate the procoagulant function, whereas light-chain cleavage is required to dissociate factor VIII from von Willebrand factor. The ki...

Von Willebrand factor (VWF) is a multimeric plasma glycoprotein that plays a central role in the initiation of blood coagulation. Through interactions between its specific functional domains, the vascular wall, coagulation factor VIII, and platelet receptors, VWF maintains hemostasis by binding to platelets and delivering factor VIII to the sites of vascular injury. In the healthy human populat...

Hitzig, W. H. and Zwinger, W.: Kongenitaler Faktor-VII-Mangel. Helv. paediat. Acta 13: 189 (1958). Macfarlane, R. G.; Biggs, R. and Bidwell, E.: Bovine antihaemophilic globulin in the treatment of haemophilia. Lancet ii: 1316 (1954). Penick, G. D. and Brinkhous, K. M.: Relative stability of plasma antihemophilic factor (AHF) under different conditions of storage. Amer. J. med. Sei. 232: 434 (19...

Background: The ABO Blood group system has been evaluated many a times for increased risk of vascular accidents and heart diseases. This study aims to prove that the reason behind the decreased risk of thrombosis in O blood group population could be the decreased levels of clotting factors in its plasma compared to other blood groups. Objective: To assess the levels of clotting factors VII, VII...

Thromb Haemost 2006; 95: 903–5 Dear Sir, The conventional treatment of haemophilia A is the replacement of human factor VIII (FVIII) derived from plasma or recombinant sources. A major complication of therapy is the development of inhibitory antibodies against substituted factor VIII, affecting 20–30% of severely affected haemophilia A patients. Typically, these antibodies develop at therapy on...

The interference of antibodies to factor VIII coagulant protein (Vlll:C) of 9 nonhemophilic patients with the binding to factor VIII coagulant antigen (VIII:CAg) of a reference hemophilic ‘251-Fab’ reagent, used in a liquid phase Vlll:CAg assay, was studied. The binding competition was estimated from immunoradiometric assay (IRMA) doseresponse slope of Vlll:CAg present in patient plasma. interf...

Viral safety is a prerequisite for manufacturing clinical antihemophilic factor VIII concentrates from human plasma. With particular regard to the hepatitis A virus (HAV), a terminal dry-heat treatment (100 degrees for 30 min) process, following lyophilization, was developed to improve the virus safety of a solvent/detergent-treated antihemophilic factor VIII concentrate. The loss of factor VII...

A number of therapeutics have been developed or are under development aiming to modulate the coagulation network to treat various diseases. We used a systems model to better understand the effect of modulating various components on blood coagulation. A computational model of the coagulation network was built to match in-house in vitro thrombin generation and activated Partial Thromboplastin Tim...